8-K
filed January 8, 2026, 6:59 PM ET
ticker CRIS
CIK 0001108205
other material
confidence high
sentiment positive
materiality 0.85
Curis raises up to $80.8M in PIPE financing; extends cash runway into 2027
CURIS INC
- Initial gross proceeds of ~$20.2M from sale of Series B Preferred Stock and warrants; potential total up to ~$80.8M if warrants exercised.
- Warrants to purchase up to 26.9M shares each (Series A, B, C) at $0.75 exercise price; exercisable after stockholder approval.
- Proceeds expected to extend cash runway into 2027; focus on Phase 2 combo study of emavusertib in CLL and PCNSL.
- Purchasers include CEO, CFO, CMO, CDO and a board member.
- PIPE proceeds believed to sustain stockholders’ equity above Nasdaq $2.5M minimum; delisting hearing pending.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
CURIS INC issued 26,926,675 shares of Common Stock of warrant to the purchasers named therein for purchase price of $1,000.00 per Security.
- Security
- warrant
- Shares
- 26,926,675 shares of Common Stock
- Purchaser
- the purchasers named therein
- Consideration
- purchase price of $1,000.00 per Security
Exact text from the filing
shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a “Security”). The Securities will be sold at a purchase price of $1,000.00 per Security to the Purchasers, which includes the Company’s Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Chief Development Officer and a member of the
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
CURIS INC issued 26,926,675 shares of the Company’s common stock of warrant to the purchasers named therein for purchase price of $1,000.00 per Security.
- Security
- warrant
- Shares
- 26,926,675 shares of the Company’s common stock
- Purchaser
- the purchasers named therein
- Consideration
- purchase price of $1,000.00 per Security
Exact text from the filing
shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a “Security”). The Securities will be sold at a purchase price of $1,000.00 per Security to the Purchasers, which includes the Company’s Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Chief Development Officer and a member of the
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
CURIS INC issued 20,195 shares of its Series B convertible non-redeemable preferred stock of preferred stock to the purchasers named therein for purchase price of $1,000.00 per Security.
- Security
- preferred stock
- Shares
- 20,195 shares of its Series B convertible non-redeemable preferred stock
- Purchaser
- the purchasers named therein
- Consideration
- purchase price of $1,000.00 per Security
Exact text from the filing
shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a “Security”). The Securities will be sold at a purchase price of $1,000.00 per Security to the Purchasers, which includes the Company’s Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Chief Development Officer and a member of the
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
CURIS INC: Filed Certificate of Designations for Series B Convertible Non-Redeemable Preferred Stock, designating 20,195 shares with specific rights, preferences, and privileges (effective 2026-01-07).
- Change
- charter amendment
- Effective
- 2026-01-07
Exact text from the filing
Pursuant to the terms of the Purchase Agreement, on January 7, 2026 (the “Filing Date”), the Company filed the Certificate of Designations with the Secretary of State of the State of Delaware designating 20,195 shares of its authorized and unissued preferred stock as Series B Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CURIS INC entered into Securities Purchase Agreement with the purchasers named therein valued at up to approximately $80.8 million (effective 2026-01-07).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the purchasers named therein
- Value
- up to approximately $80.8 million
- Effective
- 2026-01-07
Exact text from the filing
On January 7, 2026, Curis, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell an aggregate of (i) 20,195 shares of its Series B convertible non-redeemable preferred stock, par value $0.01 per share (the “Series B Preferred Stock”), (ii) Series A warrants
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.